{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-004948","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.907388+00:00","generated_at":"2026-05-27T03:13:32.199102+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AIM ImmunoTech gets safety committee nod for Phase 2 of Ampligen + Imfinzi in pancreatic cancer","bullets":["Safety committee approved Phase 2 based on Phase 1 data: no severe adverse events or dose-limiting toxicities.","Phase 2 enrollment expected to commence imminently; up to 25 patients to be enrolled.","Combination therapy uses AIM's Ampligen and AstraZeneca's Imfinzi for late-stage pancreatic cancer.","Phase 1 data showed combination generally well-tolerated; some patients had stable disease for 15+ months."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-004948","json":"https://secwatch.observer/filing/0001493152-25-004948.json","markdown":"https://secwatch.observer/filing/0001493152-25-004948.md","text":"https://secwatch.observer/filing/0001493152-25-004948.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315225004948/0001493152-25-004948-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315225004948/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T03:13:32.199102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}